Diversity of US participants in AstraZeneca-sponsored clinical trials.
Contemp Clin Trials
; 140: 107496, 2024 05.
Article
em En
| MEDLINE
| ID: mdl-38467274
ABSTRACT
BACKGROUND:
To develop medicines that are safe and efficacious to all patients, clinical trials must enroll appropriate target populations, but imbalances related to race, ethnicity and sex have been reported. A comprehensive analysis and improvement in understanding representativeness of patient enrollment in industry-sponsored trials are key public health needs.METHODS:
We assessed race/ethnicity and sex representation in AstraZeneca (AZ)-sponsored clinical trials in the United States (US) from 2010 to 2022, compared with the 2019 US Census.RESULTS:
In total, 246 trials representing 95,372 patients with complete race/ethnicity and sex records were analyzed. The proportions of different race/ethnicity subgroups in AZ-sponsored clinical trials and the US Census were similar (White 69.5% vs 60.1%, Black or African American 13.3% vs 12.5%, Asian 1.8% vs 5.8%, Hispanic 14.4% vs 18.5%). We also observed parity in the proportions of males and females between AZ clinical trials and US Census (males 52.4% vs 49.2%, females 47.6% vs 50.8%). Comparisons of four distinct therapy areas within AZ (Respiratory and Immunology [R&I]; Cardiovascular, Renal, and Metabolism [CVRM]; Solid Tumors; and Hematological Malignancies), including by trial phases, revealed greater variability, with proportions observed above and below US Census levels.CONCLUSION:
This analysis provides the first detailed insights into the representativeness of AZ trials. Overall, the proportions of different race/ethnicity and sex subgroups in AZ-sponsored clinical trials were broadly aligned with the US Census. We outline some of AZ's planned health equity initiatives that are intended to continue to improve equitable patient enrollment.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Ensaios Clínicos como Assunto
Limite:
Female
/
Humans
/
Male
País/Região como assunto:
America do norte
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article